Medicare Price ‘Negotiation’ Would Have Stymied Verzenio Advance In Early Cancer – Lilly’s Ricks
‘It takes longer than nine years’ to profit from small molecule drug R&D, company CEO maintains in arguments against the negotiation process, and its timelines, in the Senate drug pricing reform legislation.
You may also be interested in...
David Ricks says the challenging political environment is empowering regulators. The Lilly leader also talked Twitter and drug prices, in a STAT Summit interview.
Alkermes discusses oncology drug spin-off, Lilly discloses decision to halt development of a small molecule drug, and AbbVie comments on pending Medicare price negotiation for Imbruvica.
Merck & Co. CEO Rob Davis, Regeneron president George Yancopoulos, Pfizer R&D president Mikael Dolsten and others weighed in at the Galien Forum on the potential impact of the US Inflation Reduction Act on innovation.